Q1 Earnings Forecast for Repligen Issued By Leerink Partnrs

Repligen Corporation (NASDAQ:RGEN) – Equities research analysts at Leerink Partnrs issued their Q1 2026 earnings estimates for shares of Repligen in a research report issued on Thursday, July 17th. Leerink Partnrs analyst P. Souda anticipates that the biotechnology company will post earnings of $0.47 per share for the quarter. The consensus estimate for Repligen’s current full-year earnings is $1.72 per share. Leerink Partnrs also issued estimates for Repligen’s Q2 2026 earnings at $0.52 EPS, Q3 2026 earnings at $0.52 EPS and Q4 2026 earnings at $0.66 EPS.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, April 29th. The biotechnology company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.35 by $0.04. Repligen had a negative net margin of 3.93% and a positive return on equity of 4.53%. The business had revenue of $169.17 million for the quarter, compared to analysts’ expectations of $163.65 million. During the same period in the previous year, the company posted $0.28 EPS. Repligen’s revenue was up 10.4% on a year-over-year basis.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada reduced their price objective on shares of Repligen from $202.00 to $189.00 and set an “outperform” rating for the company in a research note on Wednesday, April 30th. Wolfe Research raised shares of Repligen from a “peer perform” rating to an “outperform” rating and set a $160.00 target price for the company in a research report on Tuesday, April 29th. HC Wainwright reissued a “buy” rating and set a $180.00 target price on shares of Repligen in a research report on Monday, May 5th. Evercore ISI cut their target price on shares of Repligen from $140.00 to $130.00 and set an “in-line” rating for the company in a research report on Tuesday, July 8th. Finally, JPMorgan Chase & Co. cut their target price on shares of Repligen from $200.00 to $190.00 and set an “overweight” rating for the company in a research report on Tuesday, April 29th. Five equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $170.75.

Repligen Stock Down 6.3%

RGEN stock opened at $116.25 on Friday. The company has a current ratio of 6.79, a quick ratio of 5.79 and a debt-to-equity ratio of 0.27. Repligen has a 1 year low of $102.97 and a 1 year high of $182.52. The company has a fifty day simple moving average of $124.65 and a 200 day simple moving average of $138.51. The firm has a market cap of $6.53 billion, a PE ratio of -258.33, a PEG ratio of 3.55 and a beta of 1.11.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in RGEN. Congress Asset Management Co. grew its stake in Repligen by 18.0% during the second quarter. Congress Asset Management Co. now owns 152,450 shares of the biotechnology company’s stock worth $18,962,000 after buying an additional 23,231 shares during the last quarter. Park Avenue Securities LLC bought a new stake in shares of Repligen during the second quarter valued at approximately $340,000. Krilogy Financial LLC bought a new stake in shares of Repligen during the second quarter valued at approximately $2,513,000. Osterweis Capital Management Inc. grew its stake in shares of Repligen by 18.0% during the first quarter. Osterweis Capital Management Inc. now owns 72,765 shares of the biotechnology company’s stock valued at $9,259,000 after purchasing an additional 11,080 shares during the last quarter. Finally, Strs Ohio bought a new stake in shares of Repligen during the first quarter valued at approximately $6,069,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.